TRIM21 and anemia: Antibodies to DNase1L3 were significantly associated with anemia, livedo, proteinuria, low complement levels, use of cytotoxic treatment, and a broad range of autoantibodies, including anti-dsDNA, anti-cardiolipin, lupus anticoagulant, anti-β2-glycoprotein I (B2GPI), anti-Ro52 antibodies (Fig. 1b and Supplementary Table 1).